Treffer: XGBoost-based machine learning model combining clinical and ultrasound data for personalized prediction of thyroid nodule malignancy.
J Am Coll Radiol. 2015 Dec;12(12 Pt A):1272-9. (PMID: 26419308)
Cancer Cytopathol. 2019 Jun;127(6):362-369. (PMID: 31017745)
Front Endocrinol (Lausanne). 2022 Sep 20;13:966572. (PMID: 36204114)
Ann Med. 2021 Dec;53(1):257-266. (PMID: 33410720)
Biomedicines. 2022 Aug 08;10(8):. (PMID: 36009464)
Eur Radiol. 2021 Jul;31(7):5059-5067. (PMID: 33459858)
Eur Thyroid J. 2017 Sep;6(5):225-237. (PMID: 29167761)
Oncologist. 2020 May;25(5):398-403. (PMID: 31740569)
Endocrine. 2020 Nov;70(2):256-279. (PMID: 32827126)
Clin Endocrinol (Oxf). 2023 Jun;98(6):753-762. (PMID: 36715016)
Oncologist. 2020 Sep;25(9):765-771. (PMID: 32329106)
Front Oncol. 2022 Aug 18;12:970758. (PMID: 36059607)
Thyroid. 2023 Dec;33(12):1423-1433. (PMID: 37742115)
Front Endocrinol (Lausanne). 2023 Jul 24;14:1154984. (PMID: 37554760)
Quant Imaging Med Surg. 2024 Sep 1;14(9):6311-6324. (PMID: 39281129)
Heliyon. 2024 Jan 17;10(2):e24391. (PMID: 38312537)
Rev Endocr Metab Disord. 2024 Feb;25(1):19-34. (PMID: 37957487)
Lancet Diabetes Endocrinol. 2020 Jun;8(6):468-470. (PMID: 32445733)
Gland Surg. 2019 Aug;8(4):362-369. (PMID: 31538060)
Lancet Digit Health. 2020 Jun;2(6):e279-e281. (PMID: 33328120)
Eur Thyroid J. 2022 Mar 08;11(2):. (PMID: 35113036)
Cancers (Basel). 2022 Jan 30;14(3):. (PMID: 35158985)
Cancers (Basel). 2020 Dec 28;13(1):. (PMID: 33379188)
Cancers (Basel). 2020 Oct 24;12(11):. (PMID: 33114365)
Clin Endocrinol (Oxf). 2025 Jan;102(1):79-90. (PMID: 39279486)
Genes (Basel). 2019 Sep 23;10(10):. (PMID: 31547603)
Front Endocrinol (Lausanne). 2024 Jun 14;15:1385167. (PMID: 38948526)
Clin Nucl Med. 2023 Jun 1;48(6):497-504. (PMID: 37001129)
Cancers (Basel). 2022 Oct 03;14(19):. (PMID: 36230749)
Weitere Informationen
Purpose: Thyroid ultrasound is a primary tool for screening thyroid nodules (TNs), but existing risk stratification systems have limitations. Nowadays, machine learning (ML) offers advanced capabilities to handle high-dimensional data and complex patterns. This study aimed to develop an ML model integrating clinical data and ultrasound features to improve personalized prediction of TN malignancy.
Methods: Data from 2,014 patients with TNs (2018.01-2024.01) were retrospectively analyzed, with 1,612 in the training set and 402 in the test set. Features included demographic, ultrasound, and thyroid function indices. Random Forest (RF) and Lasso regression were used for feature selection. Furthermore, six ML models (KNN, Logistic Regression, RF, Classification Tree, SVM, and XGBoost) were developed and validated via 10-fold cross-validation, evaluating performance using area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, calibration curves, and decision curve analysis (DCA).
Results: 17 variables were influential factors for diagnosing TNs. All six models exhibited satisfactory predictive performance, with their accuracy ranging from 0.761 to 0.851 and AUC from 0.755 to 0.928. Among them, the XGBoost model demonstrated the best performance, achieving an AUC of 0.928, accuracy of 0.851, sensitivity of 0.933, and specificity of 0.650. Calibration curves showed strong agreement between predicted and observed malignancy probabilities, and DCA indicated net clinical benefit across a wide risk threshold range (0.2-0.9). Additionally, we have developed the model as a web-based calculator to facilitate its practical application.
Conclusions: The XGBoost model effectively integrates multi-modal data to predict TN malignancy, offering improved accuracy and clinical utility.
(Copyright © 2025 Li, Zhou, Luo, Tan, Yin and Li.)
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.